9.4 GOLOMB B. A. (1996). Using placebos. Nature 379(6568): 765
Using placebos
SIR - I pointed out earlier (Nature
375, 530; 1995) that because placebos are unregulated and have not been shown
to be inert, an apparent positive, negative or null effect of a drug in a
placebo-controlled trial could issue instead from a negative, positive or same direction
effect of the placebo. J. H. Schoemaker (Nature 377, 98; 1995) concedes the point,
but believes it prudent to ignore this problem, because facing it might cost money.
Efforts to address the placebo problem
need not be costly, and some might even save money. Focus groups could be convened to
devise low-cost suggestions. Guidelines on what constitutes acceptable placebos could be
developed. Journals could insist that all constituents of placebo and drug be named by
weight. One or two placebo agents might be adopted as
standards, and their effects examined in detail so that these effects might be adjusted
for in analysis. Selected well-studied flavours and coatings could become
standard for use with both drug and placebo, actually reducing costs by obviating the need
to match the flavour and appearance of the placebo to each drug.
Schoemaker asserts that "in the worst
case", if a drug is credited for effects it does not produce because "by
chance" there had been negative effects of the placebo, "this may not be
harmful". Yet it may be enormously harmful if the result influences clinical
practice. In addition, it is naive to suppose that only by chance can a drug be falsely
credited because of a deleterious placebo. Pharmaceutical companies currently determine
the composition of placebos in trials of their own drugs; as billions of dollars may be at
stake in the outcome, production of the 'inert' comparison
agent by the drug company that manufactures the treatment drug under study represents a
clear conflict of interest, particularly worrying in the absence of regulations, testing
of placebo agents for inertness, or even a statement
of the placebo composition in published journal articles. These concerns might be
mitigated if there were formal regulations about placebo constituents and if production of
placebos were removed from the hands of the company
manufacturing the study drug.
Beatrice A. Golomb
Department of Medicine, University of California,
Los Angeles, B-973 Louis Factor Building,10833 Le Conte Avenue, Los Angeles,
California 90095-1736, USA
NATURE - VOL 379 - 29 FEBRUARY 1996
|